The U.S. equities market finished sharply higher Thursday, with major indexes rebounding in a rally fueled by technology-related stocks as investors cheered Microsoft’s [earnings results]( ...

Clinical-stage biopharmaceutical company Braveheart Bio plans to sell 18.75 million shares at between $15 and $17 each in its initial public offering. At the $16 midpoint of that price range, the San ...